Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: A position statement from the Nordic Transplantation Societies

Transplant International

Volumn 26, Issue 11, 2013, Pages 1049-1060

  Hornum, Mads ^a   Lindahl, Jørn P ^b   Von Zur Mühlen, Bengt ^c   Jenssen, Trond ^b,d   Feldt Rasmussen, Bo ^a  

^a Rigshospitalet   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

immunosuppression; new onset diabetes mellitus; transplantation; treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BIGUANIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; MEGLITINIDE; PREDNISOLONE; RAPAMYCIN; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; VILDAGLIPTIN; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIET THERAPY; DISORDERS OF CARBOHYDRATE METABOLISM; ETHNICITY; FAMILY HISTORY; GENOTYPE; HEPATITIS C; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SMOKING; WEIGHT GAIN; ADULT; CARDIOVASCULAR DISEASES; COMPLICATION; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN RESISTANCE; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; MIDDLE AGED; RISK FACTORS;

EID: 84886953611     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12112     Document Type: Review

References (95)

1. Davidson JA, Wilkinson A,. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 2004; 27: 805.
2. Wilkinson A, Davidson J, Dotta F, et al,. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19: 291.
3. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM,. Patient survival after renal transplantation: IV. impact of post-transplant diabetes. Kidney Int 2002; 62: 1440.
4. Cosio FG, Kudva Y, van der Velde M, et al,. New onset hyperglycaemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415.
5. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
6. Woodward RS, Schnitzler MA, Baty J, et al,. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
7. Hornum M, Jorgensen KA, Hansen JM, et al,. New-onset diabetes mellitus after kidney transplantation in denmark. Clin J Am Soc Nephrol 2010; 5: 709.
8. Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A,. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol Dial Transplant 2003; 18: 2154.
9. World Health Organization. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part I: Diagnosis and Classification of Diabetes Mellitus. World Health Organization, 1999: 65 pp.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl. 1): S64.
11. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327.
12. Selvaraj N, Bobby Z, Sridhar MG,. Increased glycation of hemoglobin in chronic renal failure: [corrected] potential role of oxidative stress. Arch Med Res 2008; 39: 277.
13. De MS, Cecchin E, Basile A, et al,. More on the increase of hemoglobin A1 in chronic renal failure: the role of acidosis. Nephron 1983; 35: 49.
14. Hoban R, Gielda B, Temkit M, et al,. Utility of HbA1c in the detection of subclinical post renal transplant diabetes. Transplantation 2006; 81: 379.
15. Valderhaug TG, Jenssen T, Hartmann A, et al,. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88: 429.
16. Bergrem HA, Valderhaug TG, Hartmann A, et al,. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010; 5: 616.
17. Baid S, Cosimi AB, Farrell ML, et al,. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066.
18. Hjelmesaeth J, Hartmann A, Kofstad J, et al,. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979.
19. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH,. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26: 30.
20. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC,. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583.
21. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM,. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732.
22. Valderhaug TG, Hjelmesaeth J, Rollag H, et al,. Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007; 84: 1125.
23. Chakkera HA, Weil EJ, Swanson CM, et al,. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011; 34: 2141.
24. Caillard S, Eprinchard L, Perrin P, et al,. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 2011; 91: 757.
25. Bayer ND, Cochetti PT, Nil Kumar MS, et al,. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 27: 90.
26. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ,. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19.
27. Steinmuller TH, Stockmann M, Bechstein WO, Settmacher U, Jonas S, Neuhaus P,. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 401.
28. Martinez-Castelao A, Hernandez MD, Pascual J, et al,. Detection and treatment of post kidney transplant hyperglycaemia: a Spanish multicenter cross-sectional study. Transplant Proc 2005; 37: 3813.
29. Hamer RA, Chow CL, Ong AC, McKane WS,. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83: 36.
30. Torres-Romero LF, Santiago-Delpin EA, de Echegaray S, et al,. HLA is not predictive of posttransplant diabetes mellitus. Transplant Proc 2006; 38: 914.
31. Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB,. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 2005; 80: 945.
32. Zelle DM, Corpeleijn E, Stolk RP, et al,. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011; 6: 898.
33. Sharif A, Moore R, Baboolal K,. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycaemia. Transplantation 2008; 85: 353.
34. Bloom RD, Lake JR,. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 2006; 6: 2232.
35. Baid-Agrawal S, Frei U, Reinke P, et al,. Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant 2009; 9: 2777.
36. Demirci MS, Toz H, Yilmaz F, et al,. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 2010; 24: E170.
37. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S,. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89: 1134.
38. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G,. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005; 5: 2433.
39. Kamar N, Toupance O, Buchler M, et al,. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092.
40. Terasaki PI, Yuge J, Cecka JM, Gjertson DW,. Cytomegalovirus antibody status and kidney transplantation. Clin Transpl 1994; 1: 509.
41. Hjelmesaeth J, Sagedal S, Hartmann A, et al,. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550.
42. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van VP,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
43. Midtvedt K, Hjelmesaeth J, Hartmann A, et al,. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004; 15: 3233.
44. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
45. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP,. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221.
46. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R,. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22: 2107.
47. Aasebo W, Midtvedt K, Valderhaug TG, et al,. Impaired glucose homeostasis in renal transplant recipients receiving basiliximab. Nephrol Dial Transplant 2010; 25: 1289.
48. Kreis H, Cisterne JM, Land W, et al,. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
49. MacDonald AS,. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
50. Teutonico A, Schena PF, Di Paolo S,. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128.
51. Romagnoli J, Citterio F, Nanni G, et al,. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006; 38: 1034.
52. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al,. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170.
53. Johnston O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
54. Shihab FS, Cibrik D, Chan L, et al,. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant 2013; 27: 217.
55. Ippoliti G, D'Armini AM, Lucioni M, Marjieh M, Vigano M,. Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection. Biologics 2012; 6: 355.
56. Cole EH, Johnston O, Rose CL, Gill JS,. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814.
57. Ducloux D, Kazory A, Chalopin JM,. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005; 79: 438.
58. Hjelmesaeth J, Hartmann A, Leivestad T, et al,. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588.
59. Valderhaug TG, Hjelmesaeth J, Hartmann A, et al,. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011; 54: 1341.
60. Kasiske BL, Anjum S, Shah R, et al,. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
61. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 3): S1.
62. Cravedi P, Perico N, Remuzzi G,. Non-immune interventions to protect kidney allografts in the long term. Kidney Int Suppl 2010; 119: S71.
63. Chueh SC, Kahan BD,. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375.
64. Holdaas H, Fellstrom B, Cole E, et al,. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929.
65. Kasiske BL, Ramos EL, Gaston RS, et al,. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 1995; 6: 1.
66. Hurst FP, Altieri M, Patel PP, et al,. Effect of Smoking on kidney transplant outcomes: analysis of the United States Renal Data System. Transplantation 2011; 92: 1101.
67. Mercado C, Jaimes EA,. Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights. Curr Hypertens Rep 2007; 9: 66.
68. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71.
69. Grotz W, Siebig S, Olschewski M, Strey CW, Peter K,. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 2004; 77: 1848.
70. Mancia G, De Backer G, Dominiczak A, et al,. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751.
71. Holley JL, Shapiro R, Lopatin WB, Tzakis AG, Hakala TR, Starzl TE,. Obesity as a risk factor following cadaveric renal transplantation. Transplantation 1990; 49: 387.
72. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30 (Suppl. 1): S42.
73. Armstrong KA, Prins JB, Beller EM, et al,. Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 2006; 1: 100.
74. Shah A, Kendall G, Demme RA, et al,. Home glucometer monitoring markedly improves diagnosis of post renal transplant diabetes mellitus in renal transplant recipients. Transplantation 2005; 80: 775.
75. Luan FL, Stuckey LJ, Ojo AO,. Abnormal glucose metabolism and metabolic syndrome in non-diabetic kidney transplant recipients early after transplantation. Transplantation 2010; 89: 1034.
76. David-Neto E, Lemos FC, Fadel LM, et al,. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84: 50.
77. Hecking M, Haidinger M, Doller D, et al,. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739.
78. Weng J, Li Y, Xu W, et al,. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753.
79. Ainla T, Baburin A, Teesalu R, Rahu M,. The association between hyperglycaemia on admission and 180-day mortality in acute myocardial infarction patients with and without diabetes. Diabet Med 2005; 22: 1321.
80. Jones KW, Cain AS, Mitchell JH, et al,. Hyperglycemia predicts mortality after CABG: postoperative hyperglycemia predicts dramatic increases in mortality after coronary artery bypass graft surgery. J Diabetes Complications 2008; 22: 365.
81. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ,. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005; 28: 810.
82. Monteiro S, Monteiro P, Goncalves F, Freitas M, Providencia LA,. Hyperglycaemia at admission in acute coronary syndrome patients: prognostic value in diabetics and non-diabetics. Eur J Cardiovasc Prev Rehabil 2010; 17: 155.
83. Malmberg K,. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512.
84. Van den Berghe G, Wouters P, Weekers F, et al,. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359.
85. Van den Berghe G, Wilmer A, Hermans G, et al,. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449.
86. Finfer S, Chittock DR, Su SY, et al,. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283.
87. Wiener RS, Wiener DC, Larson RJ,. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300: 933.
88. Finfer S, Liu B, Chittock DR, et al,. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012; 367: 1108.
89. Moghissi ES, Korytkowski MT, DiNardo M, et al,. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009; 32: 1119.
90. Hermayer KL, Egidi MF, Finch NJ, et al,. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes. J Clin Endocrinol Metab 2012; 97: 4399.
91. Turk T, Pietruck F, Dolff S, et al,. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6: 842.
92. Del PS, Pulizzi N,. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006; 5 (Suppl. 1): S20.
93. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB,. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92: e56.
94. Werzowa J, Hecking M, Haidinger M, et al,. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013; 95: 456.
95. Graefe-Mody U, Friedrich C, Port A, et al,. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13: 939.